pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cardiology · news · pharmadog
← back to Cardiology
News · Cardiology
332
stories
3h
How cost and perception could reshape the GLP-1 market
biopharma dive
6h
Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors
stat
1d
Scribe’s early-stage IPO standout defies biotech’s derisking trend
biospace
1d
STAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejection
stat
1d
STAT+: One of the most consequential years for cancer treatment, ever
stat
1d
Reduce protein to increase longevity? Nutrition experts say that’s a bad idea
stat
1d
Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
stat
1d
7 biopharma M&A deals where layoffs followed
biospace
1d
Why pediatric rare oncology outperforms in a volatile biotech market
biospace
2d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
2d
She grew up unvaccinated. Now she’s a leading voice for science — and empathy
stat
3d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
3d
STAT+: A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
stat
3d
Opinion: 8 steps to making surrogacy more ethical for everyone involved
stat
4d
EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
biospace
4d
Merck KGaA lays off 20 staffers in latest blow to US research team
fiercebiotech
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
Everything the Trump administration did on health care last week
stat
4d
How AI-enabled Software as Medical Devices are Reshaping Regulatory Routes and Medicine
biospace
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
7d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
7d
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
7d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
7d
Capricor soars on plan to amend DMD filing after adcomm setback
fiercebiotech
7d
Opinion: MAHA and insurance companies both want to treat human bodies like cars
stat
8d
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
stat
8d
Opinion: How to disrupt the health misinformation business model
stat
8d
STAT+: What Medicare incentives for AI-based devices mean for tech companies — and hospitals
stat
8d
Medtronic veteran Bill Shields crosses over to become CEO at valve disease startup
fiercebiotech
← prev
page 1 of 12
next →
